Annexon Reports Preliminary Success in Phase 3 Trial of Novel C1q Inhibitor ANX005 for Guillain-Barré Syndrome.

Quell Therapeutics progresses QEL-001, their innovative CAR-Treg cell therapy, to the efficacy phase of the LIBERATE Phase 1/2 trial in liver transplant recipients.

Virion Therapeutics Announces Encouraging Phase 1b Immunogenicity Data of New HBV Treatment VRON-0200 at EASL Congress.

Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.

AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.

Amgen announces successful phase 3 trial results for Uplizna® (inebilizumab-cdon) in treating immunoglobulin G4-related disease (IgG4-RD).

Boston Pharmaceuticals Unveils Data at EASL Congress 2024 Demonstrating BOS-580, a Long-acting FGF21 Analogue, Enhances Lipid Profiles in Phenotypic MASH Patients.

Nutcracker Therapeutics Showcases Improved Efficacy of B Cell Lymphoma Drug Candidate NTX-472 at 2024 ASCO Meeting.

Accutar Biotechnology, Inc. has shared findings from an ongoing Phase 1 clinical trial of AC699.

The European Commission has approved Biogen's QALSODY® (tofersen), a pioneering treatment for a rare genetic type of ALS.

Immunocore reveals new Phase 1 results for brenetafusp (IMC-F106C), a bispecific ImmTAC targeting PRAME, in melanoma patients previously treated with immune checkpoint inhibitors at ASCO 2024.

Actym Therapeutics revealed that the U.S. FDA allowing the commencement of a Phase 1 clinical trial for its primary drug candidate, ACTM-838.